Today: 27 June 2026
AMD stock steadies before the open after Meta AI chip deal, 160 mln-share warrant

AMD stock steadies before the open after Meta AI chip deal, 160 mln-share warrant

New York, February 25, 2026, 04:56 (ET) — Premarket

  • AMD edged higher in premarket trading, following its 8.8% surge from the previous session.
  • The Meta agreement features a performance-based warrant, contingent on both shipment milestones and specific stock-price targets.
  • Nvidia steps into the spotlight later Wednesday, with chip investors watching closely for signals on demand.

Advanced Micro Devices, Inc. shares edged up in premarket trading Wednesday, after the chipmaker disclosed a multi-year artificial intelligence chip supply agreement with Meta Platforms. The arrangement could end up giving the Facebook parent a significant equity stake.

The deal drops as AI hardware stocks twitch, investors pushing hard for proof that data-center chip demand can actually stretch beyond just a single dominant player.

Nvidia is set to report results in just a few hours—a regular catalyst that tends to swing the entire sector and can swiftly shift how investors look at spending around AI servers and accelerators.

AMD edged 0.4% higher to $214.78 in premarket moves, following a sharp 8.77% jump Tuesday that left shares finishing at $213.84. The prior session saw AMD swing between $206.50 and $216.71, with volume near 81 million shares.

AMD on Tuesday announced a deal to supply Meta with up to $60 billion worth of AI chips over five years, handing Meta the right to snap up as much as a 10% stake in AMD. “Locking in supply, diversifying away from a single vendor,” said Matt Britzman, senior equity analyst at Hargreaves Lansdown—echoing Big Tech’s scramble for hard-to-get processors. Reuters

AMD’s first rollout features a custom Instinct GPU built on the MI450 architecture, paired with its sixth-generation EPYC “Venice” server CPUs and ROCm software, all part of the company’s Helios rack-scale system. CEO Lisa Su pointed to Meta’s plans to “push the boundaries of AI at unprecedented scale.” Mark Zuckerberg, Meta’s CEO, said the collaboration allows Meta to “diversify our compute.” CFO Jean Hu told reporters the deal is set to “drive substantial multi-year revenue growth.” AMD

According to a securities filing, Meta holds a warrant allowing it to buy as many as 160 million AMD shares at just $0.01 apiece. The vesting? It depends on hitting certain shipment milestones—specifically, up to six gigawatts of Instinct GPU purchases—as well as AMD’s stock hitting price targets that reach $600 for the last tranche. Meta can exercise the option through Feb. 23, 2031, and also secured registration rights for these shares, the filing noted.

Meta’s angle here is inference—the point when an AI model spits out user responses—a process that quickly shines a spotlight on cost and energy efficiency as usage climbs. AMD, for its part, is pushing the idea that the hardware isn’t everything: custom systems and software count, too, and buyers get on board early if they trust the roadmap.

Even so, the setup isn’t one-sided. The warrant acts like a bargain share—assuming milestones come through. But there’s plenty for investors to scrutinize: dilution, tangled performance hurdles, and the reliability of those delivery timelines, especially as the AI scramble grows more chaotic.

Nvidia’s report lands later Wednesday, a key gauge for traders sizing up AI chip demand and pricing dynamics. Details on Meta’s buying pace, along with how swiftly AMD can deliver MI450-based systems, look set to dictate AMD’s trajectory from here.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

27 June 2026
Lucid surged 15.6% Friday, adding $312 million in equity value—almost double the $158 million in annualized savings from this week’s restructuring plan that cut 18% of its U.S. workforce. Friday’s volume equaled 54% of reported short interest, but the rally outpaced cost-cutting fundamentals, leaving less room for further gains based solely on headcount cuts.
Court ruling on student loans hits private lenders’ health grad loan push

Court ruling on student loans hits private lenders’ health grad loan push

27 June 2026
Judge blocks narrow “professional degree” rule, letting more health-care grad students keep higher federal loan caps; $7.87B in 2023-24 borrowing above new limits remains in federal market, trimming but not eliminating the $4.5B-$5B annual private loan growth Sallie Mae projected from Grad PLUS loan cuts.
Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus
Previous Story

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus

SanDisk stock rises as CEO flags multi-year data-center deals after Citron short call
Next Story

SanDisk stock rises as CEO flags multi-year data-center deals after Citron short call

Go toTop